Teva Pharmaceuticals
TEVA
447 hedge funds and large institutions have $6.16B invested in Teva Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 67 funds opening new positions, 132 increasing their positions, 144 reducing their positions, and 47 closing their positions.
43% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 47
9% more capital invested
Capital invested by funds: $5.66B → $6.16B (+$501M)
5% more funds holding in top 10
Funds holding in top 10: 19 → 20 (+1)
2.78% more ownership
Funds ownership: 49.48% → 52.26% (+2.8%)
3% more funds holding
Funds holding: 435 → 447 (+12)
5% less call options, than puts
Call options by funds: $165M | Put options by funds: $174M
8% less repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 144
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$99.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$80M |
| 3 |
Millennium Management
New York
|
+$48.7M |
| 4 |
GAM
Goldentree Asset Management
New York
|
+$36.2M |
| 5 |
MRCP
Maple Rock Capital Partners
Toronto,
Ontario, Canada
|
+$24.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$104M |
| 2 |
D.E. Shaw & Co
New York
|
-$42.2M |
| 3 |
ACM
Abrams Capital Management
Boston,
Massachusetts
|
-$18.4M |
| 4 |
RCMU
Rokos Capital Management (UK)
London,
United Kingdom
|
-$13.9M |
| 5 |
Jane Street
New York
|
-$13.6M |
TEVA Hedge Fund Activity: Q4 2023 in Review
447 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q4 2023, worth a combined $6.16B — up 8.8% from $5.66B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new TEVA positions and 47 closed out — a net gain of 20 holders — while 132 added to existing stakes and 144 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $99.4M. The largest seller was Camber Capital Management, exiting entirely with an estimated $104M sold.
- 447 institutional investors held Teva Pharmaceuticals (TEVA) as of Q4 2023, up from 435 in Q3 2023.
- Funds reported $6.16B of Teva Pharmaceuticals stock for Q4 2023, up 8.8% quarter-over-quarter.
- 67 funds opened new Teva Pharmaceuticals positions in Q4 2023 and 47 closed out, a net change of +20 holders.
- The largest Teva Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $99.4M added.
- The largest Teva Pharmaceuticals seller in Q4 2023 was Camber Capital Management, an estimated $104M sold.
Based on aggregated 13F filings for Q4 2023.